Selected Grants
A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON'S DISEASE
Clinical TrialPrincipal Investigator · Awarded by Sage Therapeutics · 2023 - 2026Web-based Automated Imaging Differentiation of Parkinsonism
ResearchPrincipal Investigator · Awarded by University of Florida · 2021 - 2026Huntington's Disease Society of America- Center of Excellence (Level 2)
Public ServicePrincipal Investigator · Awarded by Huntington's Disease Society of America · 2023 - 2025A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington¿s Disease
Clinical TrialPrincipal Investigator · Awarded by Sage Therapeutics · 2022 - 2025A Phase 3, Long-Term, Randomized, Double-Blind, Placebo-Controlled trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia
Clinical TrialPrincipal Investigator · Awarded by Biohaven Pharmaceuticals · 2019 - 2025Open Label Rollover Study of Valbenazine for the treatment of HD
Clinical TrialPrincipal Investigator · Awarded by Neurocrine Biosciences, Inc. · 2020 - 2025Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort (A CHDI Foundation Project)
Clinical TrialPrincipal Investigator · Awarded by CHDI Foundation · 2012 - 2025PRidopidine Outcome On Function in Huntington Disease (PROOF-HD)
Clinical TrialPrincipal Investigator · Awarded by Prilenia Therapeutics · 2020 - 2025Phase 2b, 12 Week, Double-blind, Placebo-Controlled, Randomized, Parallel-group, MultiCenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor
Clinical TrialPrincipal Investigator · Awarded by Cavion, Inc · 2022 - 2024Enabling Efficient, Fast, Biocompatible Exosome Separation via Acoustofluidics
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2024A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects with, or at Risk for, Manifest Huntington's Disease
Clinical TrialPrincipal Investigator · Awarded by Annexon Biosciences · 2020 - 2022Huntington's Disease Society of America- Center of Excellence (Level 2)
ResearchPrincipal Investigator · Awarded by Huntington's Disease Society of America · 2015 - 2022A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease
Clinical TrialPrincipal Investigator · Awarded by Neurocrine Biosciences, Inc. · 2019 - 2022A Phase 2, multi-center, randomized, double blind, placebo controlled study in subjects with late prodromal and early manifest Huntington Disease )HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503
Clinical TrialPrincipal Investigator · Awarded by Vaccinex, Inc. · 2015 - 2021A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease. (SPARK)
Clinical TrialPrincipal Investigator · Awarded by Biogen, Inc. · 2018 - 2021ROPAD (Rostock International Parkinson's Disease Study): An International, MultiCenter, Epidemiological Observational Study
Clinical TrialPrincipal Investigator · Awarded by Centogene AG · 2019 - 2021A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2019 - 2020A Randomized, double-blind, placebo-controlled trial of urate elevating inosine treatment to show clinical decline in early Parkinson Disease
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2015 - 2020A Randomized,Double-Blind,Placebo-Controlled,Phase IIa,Parallel Group, Two-Cohort Study to Define the Safety, Tolerability,Clinical and Exploratory Biological Activity of the ChronicAdministration of Nilotinib in Participants with Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Michael J. Fox Foundation for Parkinson's Research · 2017 - 2020Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)
Clinical TrialPrincipal Investigator · Awarded by Eli Lilly and Company · 2018 - 2019A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in Subjects with Parkinson's Disease and Excessive Sleep
ResearchPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2017 - 2019Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects with Parkinson's Disease Psychosis
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2017 - 2019An Open label, Long Term Safety Study of SD-809 Er in Subjects wtih Chorea associated with Huntington's Disease.
Clinical TrialPrincipal Investigator · Awarded by Auspex Pharmaceuticals, Inc. · 2013 - 2019A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects with Early Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Biogen Idec Inc. · 2017 - 2019A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2018A Phase 3, Long-term, Open-label Study of Istradefylline in subjects with moderate to Severe Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Kyowa Hakko Kirin Pharma Co, Ltd. · 2016 - 2018A Ph.3,Multicenter,Randomized,Doubleblind,Placebo-controlledStudy with anOpenlabelPhase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in LevodopaTreated patients with Parkinson's disease ExperiencingEndofdose "Wearing Off"
Clinical TrialPrincipal Investigator · Awarded by Biotie Therapies Corp. · 2015 - 2018Novel Combinatorial Screening for NTFs, NPCs, MMPs, and CCs in relevance to Autoantibodies in the Serum and CSF of Veterans with GWI
ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2018A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"
Clinical TrialPrincipal Investigator · Awarded by Biotie Therapies Corp. · 2017 - 2018National Parkinson Foundation Center of Excellence Grant
Public ServicePrincipal Investigator · Awarded by National Parkinson Foundation · 2017 - 2018OL Phase 3 Study Long-Term Safety of APL-130277 in Levodopa responsive patients with Parkinson's Disease Complicated by Motor Fluctuations- (OFF episodes)
Clinical TrialPrincipal Investigator · Awarded by Cynapsus Therapeutics Inc. · 2015 - 2018SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Clinical TrialPrincipal Investigator · Awarded by Biotie Therapies Corp. · 2016 - 2018A Randomized, Double-Blind, Placebo-controlled Study of SD-809 (Dutetrabenazine) for the Treatement of Moderate to Severe Tardive Dyskinesia
Clinical TrialPrincipal Investigator · Awarded by Auspex Pharmaceuticals, Inc. · 2014 - 2016A Phase 3, Randomized, Double-blind, Placebo controlled, Parrallel, Fixed Dose Study to Assess the Efficacy, Safety and Tolerability of NBI 98854 for the treatment of Tardive Dyskinesia
Clinical TrialPrincipal Investigator · Awarded by Neurocrine Biosciences, Inc. · 2014 - 2015An Open-Label, Long-Term Safety Study of SD-809 (Dutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Clinical TrialPrincipal Investigator · Awarded by Auspex Pharmaceuticals, Inc. · 2014 - 2015A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to assess sustained effects of droxidopa therapy
Clinical TrialPrincipal Investigator · Awarded by Chelsea Therapeutics · 2014 - 2015Creatine Safety, Tolerability and Efficacy in Huntington's Disease: CREST-E
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2014 - 2015A Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Scion NeuroStim LLC · 2014 - 2015Parkinson's Disease Neuroprotection Clinical Trial (Closeout Activities Budget)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2014Genetics and epidemiology of essential tremor
ResearchCo Investigator · Awarded by National Institutes of Health · 2002 - 2007External Relationships
- Deep Brain Innovations
- GemVax
- HD Reach. Started on Board of Director in January 2020.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.